Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Measurable residual disease intervention in AML: a new therapeutic horizon.

Blood - 1 Jan 2026

Wei Andrew H, Iland Harry J, DiNardo Courtney D, Reynolds John

Abstract excerpt

ABSTRACT: Acute myeloid leukemia (AML) is a polyclonal malignancy marked by high relapse rates despite initial morphologic remission. Although measurable residual disease (MRD) is an established prognostic tool, increasing evidence supports a role for preemptive, MRD-directed therapy. AML monitoring is hampered by the absence of a universal MRD marker, necessitating a more personalized approach. NPM1 is suited to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Bridged Bicyclo Compounds, Heterocyclic
Share to Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasm, Residual

Share to Nuclear Proteins

Share to Nucleophosmin

Share to Sulfonamides

Source

Identifiers

PMID: 41105915
DOI: 10.1182/blood.2025029010

Genes

FLT3
KMT2A
NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Measurable residual disease intervention in AML: a new therapeutic horizon.PMID 41105915Read ↗

Measurable residual disease testing in acute myeloid leukemia: current state, foundational models, and tools for future development.Semantic proximity Read ↗

Prognostic and Therapeutic Implications of Measurable Residual Disease Detection Across Hematologic Malignancies: Clinical Impact on Relapse Prediction and Survival OutcomesSemantic proximity Read ↗

Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.Semantic proximity Read ↗

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.Semantic proximity Read ↗

Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient.Semantic proximity Read ↗

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.Semantic proximity Read ↗

Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaSemantic proximity Read ↗

Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia.Semantic proximity Read ↗

Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study.Semantic proximity Read ↗

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutationsSemantic proximity Read ↗

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.Semantic proximity Read ↗

Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and PerspectivesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.